Personalized Cholestatic Disease Management Platform

A comprehensive system for diagnosing, treating, and managing cholestatic diseases through personalized treatment plans, real-time monitoring, and predictive analytics, revolutionizing the standard of care for patients with PBC and PSC.

The original patent addressed the treatment of cholestatic diseases, specifically PBC and PSC, with a focus on pharmaceutical interventions. However, the limitations of these treatments, including inadequate response rates and side effects, highlight the need for a more holistic and patient-centric approach. The present inventive concept addresses these limitations by introducing a personalized disease management platform that integrates diagnostic, therapeutic, and monitoring components to provide a tailored treatment experience for each patient.

The proposed platform consists of four interconnected modules: 1) a diagnostic module for identifying a patient's specific disease subtype and response to existing therapies; 2) a treatment planning module for generating a customized treatment plan based on the patient's profile; 3) a monitoring module for tracking treatment efficacy and adjusting the treatment plan accordingly; and 4) a predictive analytics module for forecasting treatment outcomes and identifying potential complications. The platform leverages machine learning algorithms, real-world evidence, and biomarker data to provide a precise and adaptive treatment approach. Additionally, the platform includes a wearable device for real-time bile flow monitoring, a personalized nutrition and lifestyle planning system, and a closed-loop system for optimizing treatment based on patient data and predictive modeling.

The present inventive concept introduces a paradigm shift in the treatment of cholestatic diseases by moving from a one-size-fits-all pharmaceutical approach to a personalized, data-driven, and adaptive management platform. The integration of diagnostic, therapeutic, and monitoring components, combined with predictive analytics and machine learning, provides a novel and non-obvious solution that addresses the limitations of existing treatments.

Alternative embodiments of the platform could include varying the types of diagnostic tests, treatment modalities, and monitoring devices used. Additionally, the platform could be adapted for use in other diseases characterized by impaired bile flow or liver function. Variations of the predictive analytics module could incorporate different machine learning algorithms or data sources to improve treatment outcome forecasting.

The personalized cholestatic disease management platform has significant commercial potential in the pharmaceutical, medical device, and healthcare industries. The platform could be marketed as a comprehensive disease management solution for patients with PBC and PSC, offering a competitive advantage over existing treatments. The market potential is substantial, with an estimated 1.5 million patients worldwide living with PBC and PSC.